Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Upgraded by HC Wainwright

Key Points

• Fulcrum Therapeutics received an upgrade from HC Wainwright, moving from a "neutral" to a "buy" rating, with a new target price of $12.00, indicating a potential upside of 55.26% from its current price.
• In addition to HC Wainwright, several other analysts have also upgraded Fulcrum Therapeutics, with Cantor Fitzgerald setting a price target of $10.00 and Piper Sandler raising their target to $9.00.
• Fulcrum Therapeutics' stock is currently trading at $7.73, down 1% during midday trading, and the company reported earnings of ($0.28) per share, surpassing analyst expectations.

HC Wainwright upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC - Free Report) from a neutral rating to a buy rating in a research note released on Tuesday, Marketbeat.com reports. The brokerage currently has $12.00 price objective on the stock, up from their prior price objective of $4.00. HC Wainwright also issued estimates for Fulcrum Therapeutics' Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($1.26) EPS, FY2028 earnings at ($0.96) EPS and FY2029 earnings at ($0.65) EPS.

Other equities analysts have also recently issued reports about the stock. Leerink Partnrs raised shares of Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Friday, May 23rd. Leerink Partners raised shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and raised their price objective for the company from $4.00 to $12.00 in a research note on Friday, May 23rd. Cantor Fitzgerald raised shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price objective on the stock in a research note on Thursday, May 15th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $9.00 price objective (up from $6.00) on shares of Fulcrum Therapeutics in a research note on Thursday, May 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $7.57.

Fulcrum Therapeutics Trading Up 1.5%

Shares of FULC traded up $0.10 during mid-day trading on Tuesday, hitting $6.83. 1,006,251 shares of the company traded hands, compared to its average volume of 954,870. Fulcrum Therapeutics has a one year low of $2.32 and a one year high of $10.13. The business has a 50-day moving average of $7.17 and a 200 day moving average of $4.99. The stock has a market capitalization of $369.43 million, a price-to-earnings ratio of -5.60 and a beta of 2.47.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. As a group, analysts anticipate that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FULC. American Century Companies Inc. lifted its holdings in Fulcrum Therapeutics by 5.9% during the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company's stock worth $567,000 after acquiring an additional 6,770 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Fulcrum Therapeutics by 34.4% during the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company's stock worth $161,000 after acquiring an additional 8,761 shares during the period. ADAR1 Capital Management LLC raised its holdings in shares of Fulcrum Therapeutics by 177.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 196,248 shares of the company's stock worth $922,000 after acquiring an additional 125,446 shares during the period. Mariner LLC acquired a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth $78,000. Finally, Zacks Investment Management acquired a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth $99,000. 89.83% of the stock is currently owned by institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.